XERS (Xeris Biopharma Holdings) Float Percentage Of Total Shares Outstanding: 96.64% (As of Jul. 12, 2026)


XERS Xeris Biopharma Holdings Inc XERS
71 GF Score
Price $8.35
GF Value $5.19
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings Float Percentage Of Total Shares Outstanding?

Xeris Biopharma Holdings XERS -3.30% 71 Float Percentage Of Total Shares Outstanding is 96.64% as of Jul. 12, 2026. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.19 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xeris Biopharma Holdings's float shares is 166.84 Mil. Xeris Biopharma Holdings's total shares outstanding is 172.64 Mil. Xeris Biopharma Holdings's float percentage of total shares outstanding is 96.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xeris Biopharma Holdings's Insider Ownership is 8.56%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xeris Biopharma Holdings's Institutional Ownership is 67.43%.

XERS
71GF Score
Xeris Biopharma Holdings Inc XERS
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xeris Biopharma Holdings Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Xeris Biopharma Holdings's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=166.84/172.64
=96.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 96.64% mean?
Xeris Biopharma Holdings (XERS) has a Float Percentage Of Total Shares Outstanding of 96.64% as of Jul. 12, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Xeris Biopharma Holdings and its competitors.
Is Xeris Biopharma Holdings' Float Percentage Of Total Shares Outstanding too high?
Xeris Biopharma Holdings' current Float Percentage Of Total Shares Outstanding is 96.64%. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Float Percentage Of Total Shares Outstanding compare to PAHC and PRGO?
Xeris Biopharma Holdings' Float Percentage Of Total Shares Outstanding of 96.64% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Drug Manufacturers company?
A good Float Percentage Of Total Shares Outstanding depends on the Drug Manufacturers industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Xeris Biopharma Holdings and its competitors. Xeris Biopharma Holdings's current Float Percentage Of Total Shares Outstanding is 96.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.19, compared to a current price of $8.35 — trading 60.9% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 96.64%. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Float Percentage Of Total Shares Outstanding is 96.64% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of $8.35 is trading 60.9% above its estimated GF Value™ of $5.19. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for XERS:

  • Float Percentage Of Total Shares Outstanding: 96.64%
  • GF Value™: $5.19 vs. price of $8.35 (60.9% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Other Exchanges 0A8E:UK2B30:Germany
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score

Get the complete analysis for XERS

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.35
Price
$5.19
GF Value